Strategic merger Leverage the Inscripta-Manus merger to position Manus as a one-stop platform for end-to-end biomanufacturing and commercialization, presenting a unified value proposition to potential customers seeking scalable bio-alternative production.

Commercial momentum Highlight the merged entity's focus on scaled profitability and commercialized products in next-generation industrial biotechnology to attract customers looking for proven pathways from development to market.

Integrated tech Target buyers with needs for genome engineering and cell factory capabilities by emphasizing the combination of whole-genome engineering with established biomanufacturing platforms for faster product development.

Strategic partnerships Capitalize on past and ongoing collaborations (e.g., with Bedoukian Bio) to showcase a track record of co-development, sustainable production, and capability to deliver naturally produced ingredients at scale.

Financial resilience Audience focus on the company's substantial funding and recent strategic shifts, framing investment signals and risk management as a gateway to scalable projects with potential for accelerated R&D-to-market timelines.